Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $94.21, for a total transaction of $235,525.00. Following the transaction, the executive vice president now owns 4,833 shares in the company, valued at $455,316.93. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Matt Scribner also recently made the following trade(s):

  • On Friday, June 16th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $91.54, for a total transaction of $228,850.00.

Shares of Inogen, Inc (INGN) opened at 95.22 on Friday. The firm has a 50-day moving average of $93.50 and a 200-day moving average of $79.08. The company has a market cap of $1.96 billion, a P/E ratio of 85.17 and a beta of 1.04. Inogen, Inc has a 12-month low of $50.01 and a 12-month high of $97.71.

Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, May 9th. The medical technology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.15. The firm had revenue of $52.50 million during the quarter, compared to the consensus estimate of $49.06 million. Inogen had a net margin of 9.32% and a return on equity of 11.67%. The company’s revenue was up 22.1% on a year-over-year basis. During the same quarter last year, the company earned $0.12 earnings per share. Analysts predict that Inogen, Inc will post $1.09 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Inogen, Inc (INGN) EVP Sells $235,525.00 in Stock” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/07/23/inogen-inc-ingn-evp-sells-235525-00-in-stock.html.

INGN has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 11th. J P Morgan Chase & Co lifted their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Stifel Nicolaus lifted their target price on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $83.00 target price on shares of Inogen in a report on Wednesday, April 5th. Finally, Sidoti initiated coverage on shares of Inogen in a report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $91.60.

Several institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new position in Inogen during the first quarter valued at $109,000. Victory Capital Management Inc. increased its position in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after buying an additional 459 shares during the last quarter. State of Alaska Department of Revenue increased its position in Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock valued at $138,000 after buying an additional 70 shares during the last quarter. Jane Street Group LLC acquired a new position in Inogen during the first quarter valued at $203,000. Finally, Guggenheim Capital LLC acquired a new position in Inogen during the fourth quarter valued at $211,000.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.